We’ve developed a new approach to CD47 blockade that is designed to maximize clinical activity and minimize toxicities

Our goal is to transform cancer treatment options for patients by developing evorpacept (ALX148) as a foundational checkpoint immunotherapy

Evorpacept Mechanism of Action

ALX Oncology was founded by a team of industry veterans to address fundamental challenges in blocking CD47 and to realize the full potential of this therapeutic target.

Cancer cells employ CD47, a cell surface protein, as a “don’t eat me” signal to evade detection by the immune system. ALX is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. We believe our lead product candidate, evorpacept (ALX148), will have a wide therapeutic window to block the “don’t eat me” signal on cancer cells, and to leverage the immune activation of broadly used anti-cancer agents through combination strategies. Based on our clinical results to date in multiple oncology indications showing encouraging anti-tumor activity and tolerability, our strategy is to pursue evorpacept as a potentially critical component for future combination treatments in oncology.

Latest News updated at 13:33:00 UTC

Aug 15, 2022

ALX Oncology and Quantum Leap Healthcare Collaborative™ Announce the Selection of Evorpacept in the I-SPY-P1 TRIAL in Combination with Enhertu® in Breast Cancer

Aug 11, 2022

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

Aug 08, 2022

ALX Oncology Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights

Twitter

ALX Oncology and Quantum Leap Healthcare Collaborative™ announce the selection of evorpacept (ALX148) in the I-SPY-P1 TRIAL in combination with ENHERTU® (fam-trastuzumab deruxtecan-nxki) in breast cancer: https://bit.ly/3Pp8Tjo

ALX Oncology announced the initiation of a Phase 2 investigator-sponsored study of evorpacept (ALX148) in combination with ERBITUX® (cetuximab) and KEYTRUDA® (pembrolizumab) in patients with refractory microsatellite stable metastatic colorectal cancer: https://bit.ly/3Abicz4

ALX Oncology today reported financial results for the second quarter ended June 30, 2022 and provided clinical development and operational highlights: https://bit.ly/3p5b0OI

Load More

Our Technology

ALX Oncology’s fusion proteins are engineered to bind CD47 with significantly greater affinity than natural SIRPα. Our lead candidate, evorpacept, is an intravenously administered fusion protein containing two engineered high affinity CD47 binding domains of SIRPα linked to an inactive Fc region of human immunoglobulin.

LEARN MORE